drugset
drugset / Trial / NCT05496426

A Study of KL130008 in Adults With Severe Alopecia Areata

NCT05496426 ↗

Phase 2 Terminated 114 enrolled Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess KL130008 is safe and effective in adults with severe alopecia areata

Timeline

Start
2022-11-09
Primary completion
2024-04-16
Completion
2024-04-16

Outcome

Outcome not reported

Stopped (Business): “This adjustment to the company's development strategy is unrelated to safety or efficacy.”

Drugs

EvaluationDrugModalityDoseRoute
Subject KL130008 Unknown — Oral

Indications

alopecia areata